Humanigen rises on deal enabling access to its COVID-19 drug

Humanigen

08/10/2021 11:27

** Shares of biopharmaceutical co Humanigen  HGEN.O  up 5.8%
at $6.73 premarket - set to have its first week in green after a
streak of five consecutive weekly losses
    ** Humanigen signs a contract with Clinigen Group plc
 CLINC.L  for LenzMAP, a program that will enable CLINC access
to HGEN's drug lenzilumab on a case-by-case basis for
hospitalized patients with COVID-19 in 16 European countries
 urn:newsml:reuters.com:*:nBw6VysSla
    ** HGEN is developing lenzilumab as a treatment for the
severe immune reaction in hospitalized COVID-19 patients
    ** Under the terms of the agreement, Clinigen will manage
key elements of the program including regulatory oversight,
logistics and access management 
    ** Up to Thursday's close, HGEN shares have lost ~64% and
CLINC dropped ~7% YTD

 (Reporting by Bansari Mayur Kamdar)
 ((BansariMayur.Kamdar@thomsonreuters.com;))